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Purpose: The aim of this “Year in Review” article is to summarize and discuss the implications of
biochemical marker related articles published between the Osteoarthritis Research Society International
(OARSI) 2015 Congress in Seattle and the OARSI 2016 Congress in Amsterdam.
Methods: The PubMed/MEDLINE bibliographic database was searched using the combined keywords:
‘biomarker’ and ‘osteoarthritis’. The PubMed/MEDLINE literature search was conducted using the
Advanced Search Builder function (http://www.ncbi.nlm.nih.gov/pubmed/advanced).
Results: Over two hundred new biomarker-related papers were published during the literature search
period. Some papers identiﬁed new biomarkers whereas others explored the biological properties and
clinical utility of existing markers. There were speciﬁc references to several adipocytokines including
leptin and adiponectin. ADAM Metallopeptidase with Thrombospondin Type 1 motif 4 (ADAMTS-4) and
aggrecan ARGS neo-epitope fragment (ARGS) in synovial ﬂuid (SF) and plasma chemokine (CeC motif)
ligand 3 (CCL3) were reported as potential new knee biomarkers. New and reﬁned proteomic technol-
ogies and novel assays including a ﬂuoro-microbead guiding chip (FMGC) for measuring C-telopeptide of
type II collagen (CTX-II) in serum and urine and a novel magnetic nanoparticle-based technology (termed
magnetic capture) for collecting and concentrating CTX-II, were described this past year.
Conclusion: There has been steady progress in osteoarthritis (OA) biomarker research in 2016. Several
novel biomarkers were identiﬁed and new technologies have been developed for measuring existing
biomarkers. However, there has been no “quantum leap” this past year and identiﬁcation of novel early
OA biomarkers remains challenging. During the past year, OARSI published a set of recommendations for
the use of soluble biomarkers in clinical trials, which is a major step forward in the clinical use of OA
biomarkers and bodes well for future OA biomarker development.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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nary Medicine, University of
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Osteoarthritis (OA) is a low-grade inﬂammatory disease of
synovial joints and the most common form of arthritis1. It is a
leading cause of chronic pain and physical disability in older in-
dividuals2. OA is one of the most costly and disabling forms of
joint disease, being far more common than rheumatoid arthritis
(RA) and other forms of joint disease3. It is characterized by
progressive deterioration and loss of articular cartilage4 with
concomitant structural and functional changes in the entire joint,
including the synovium, meniscus (in the knee), periarticular
ligaments, and subchondral bone5. Cohort studies havesearch Society International. This is an open access article under the CC BY-NC-ND
Abbreviations
ADAMTS-4 ADAM Metallopeptidase with Thrombospondin
Type 1 motif 4
ARGS aggrecan ARGS neo-epitope fragment
AUC area under the curve
C3M MMP-degraded type III collagen
CCL3 chemokine (CeC motif) ligand 3
CHECK Cohort Hip and Cohort Knee
Col2-1 NO2 nitrated type II collagen degradation fragment
COMP cartilage oligomeric matrix protein
COX-2 cyclooxygenase-2
CRP C-reactive protein
CRPM MMP-degraded C-reactive protein
CTX-II C-telopeptide of type II collagen
DMOADs disease-modifying osteoarthritis drugs
FMGC ﬂuoro-microbead guiding chip
FNIH Foundation for the National Institutes of Health
HA hyaluronan, hyaluronic acid
hsCRP high-sensitivity C-reactive protein
IL-1b interleukin-1b
IL-1Ra interleukin-1 receptor antagonist
IL-4 interleukin-4
IL-6 interleukin-6
IL-36a interleukin-36a
JSW joint space width
LCeMS liquid chromatographyemass spectrometry
MIA monoiodoacetate
MMPs matrix metalloproteinases
MMP-1 matrix metalloproteinase 1
MMP-3 matrix metalloproteinase 3
MPO myeloperoxidase
MRI magnetic resonance imaging
MS mass spectrometry
MSD musculoskeletal disease
NF-kB nuclear factor kB
NIH National Institutes of Health
NOS-2 nitric oxide synthase 2
NTX-I N-terminal telopeptide of type I collagen
OA osteoarthritis
OAI Osteoarthritis Initiative
OARSI Osteoarthritis Research Society International
PIIANP N-terminal propeptide of collagen IIA
RA rheumatoid arthritis
s serum
S100-A6 S100 Calcium Binding Protein A6
SF synovial ﬂuid
SME synovial membrane explant
TNF-a tumor necrosis factor-a
u urinary
ucMGP uncarboxylated matrix Gla-protein
VAS visual analogue scale
VDAC voltage-dependent anion-selective channel
WAT white adipose tissue
WOMAC Western Ontario and McMaster Universities Arthritis
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Fig. 1. New deﬁnition of OA, as endorsed by OARSI. This ﬁgure highlights the re-
lationships between the disease and illness components of OA. The molecular
component represents the silent and asymptomatic early stage of OA. Molecular
A. Mobasheri et al. / Osteoarthritis and Cartilage 25 (2017) 199e208200demonstrated that age, obesity and metabolic disease are major
risk factors for the development of OA6,7.
Although OA has been viewed as a “wear and tear” disease for
many decades, it is now generally accepted to be an inﬂammatory
and biomechanical whole-organ disease1,8e10 associated with sys-
temic co-morbidities and death11. The pathogenesis and progres-
sion of OA is inﬂuenced by a number of factors including bone
shape and joint dysplasia12, obesity13, synovitis14e16, complement
proteins17, inﬂammatory mediators1,18, inﬂammaging19,20, innate
immunity21, low-grade inﬂammation8 induced by metabolic syn-
drome1,22 and diabetes mellitus23.
The Osteoarthritis Research Society International (OARSI)d has
recently endorsed a new deﬁnition of OA and launched an initiative
to critically evaluate and standardize pre-existing deﬁnitions of OA.
“Osteoarthritis is a disorder involving movable joints characterized by
cell stress and extracellular matrix degradation initiated by micro- and
macro-injury that activates maladaptive repair responses including
pro-inﬂammatory pathways of innate immunity. The disease mani-
fests ﬁrst as a molecular derangement (abnormal joint tissue meta-
bolism) followed by anatomic, and/or physiologic derangements
(characterized by cartilage degradation, bone remodeling, osteophyte
formation, joint inﬂammation and loss of normal joint function), that
can culminate in illness”24 (Fig. 1). OARSI anticipates that this
updated deﬁnition of the disease process will be subject to further
critique and reﬁnement as new scientiﬁc and clinical information
emerges and our knowledge of OA pathogenesis and progression
expands.
It is clear that OA is a heterogeneous disease with a variety of
pathophysiologic drivers leading to multiple phenotypes, many of
which may overlap in patients25 (Fig. 2). Each OA phenotype mayd https://www.oarsi.org.potentially be treated and targeted differently, paving the way for
the development of stratiﬁed medicines for OA26. Some of these
phenotypes will be amenable to pharmacologic intervention but
others are less likely to respond to drugs27. The key aim of OARSI
and the OA research community is to deﬁne and characterize OA
phenotypes, develop novel, speciﬁc and sensitive disease end-
points, improve the design of OA clinical trials, identify patients
that respond to treatment and thus alleviate roadblocks to devel-
opment and clinical evaluation of disease-modifying osteoarthritis
drugs (DMOADs)28e30.changes precede the anatomic and physiologic aspects by years or even decades. This
creates a challenge for detecting the disease early and an opportunity for ﬁnding new
early marker of disease. Figure adapted from24 with the kind permission of Dr Virginia
Kraus.
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Fig. 2. OA phenotypes. OA is a heterogeneous disease with a variety of pathophysi-
ologic drivers leading to multiple phenotypes, many of which may overlap in patients.
Each phenotype may be treated and targeted differently, paving the way for patient
“stratiﬁcation” and the development of “precision” medicines for OA. Some of these
will be amenable to pharmacologic intervention but others may be less likely to
respond to drugs.
e http://www.fnih.org/what-we-do/current-research-programs/oai.
f http://www.fnih.org/what-we-do/current-research-programs/biomarkers-
consortium-oa.
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identiﬁcation and selection of fast progressors for treatment31.
Articular cartilage loss or damage in OA is detected by radiography
and measuring decreases in joint space width (JSW) on the radio-
graph, the so-called “gold standard”. In clinical practice, OA is
diagnosed radiographically when clinical signs of pain and loss of
mobility have already appeared. However, by this stage the joint is
actively responding to the injury. Studies have shown that radio-
graphic changes over time are small, and occur in only a subset of
patients (progressors), but quantitative JSW measurements have
been shown to correlate with 4-year clinical outcomes32, ﬁndings
that suggest early treatment with DMOADs are necessary to inﬂu-
ence outcomes.
The majority of patients enrolled in OA clinical studies do not
progress radiographically (or clinically) during trials that typically
last 2e3 years (even changes that may occur over 5 years can be
difﬁcult to quantify). Although magnetic resonance imaging (MRI)
is increasingly used to evaluate disease progression33, radiography
still remains the required tool for OA diagnosis and efﬁcacy
assessment in OA clinical trials. Therefore, we need to develop
sensitive and predictive biochemical marker tests and assays to
optimize these trials (e.g., patient stratiﬁcation). Moreover, such
biomarkers could ultimately be an alternative for the current
radiographic approach and prompt earlier, more targeted and
personalized treatments34,35.
In 2001 the Biomarkers Deﬁnitions Working Group deﬁned a
biomarker as a characteristic that is objectively measured and
evaluated as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic interven-
tion36. Biomarkers have the capacity to detect early joint degra-
dation in degenerative diseases such as OA. They can provide useful
diagnostic and prognostic information by reﬂecting disease rele-
vant biological activity in the joint and predict the course of disease
progression. In addition, they can serve as surrogate endpoints in
the discovery and development process for DMOADs37.The National Institutes of Health (NIH)-funded OA Biomarkers
Network has proposed the “BIPEDs” biomarker classiﬁcation
(which stands for Burden of Disease, Investigative, Prognostic,
Efﬁcacy of Intervention, Diagnostic and safety), and offered sug-
gestions on optimal study design and analytic methods for use in
OA research and subsequent papers have used this classiﬁcation to
describe the potential usage of selected biomarkers37e39. This
“Year in Review” article is a narrative review of the biochemical
marker papers published between the OARSI 2015 Congress held
from 30 April to 3 May 2015 in Seattle, Washington and the OARSI
2016meeting, held from 31March to 3 April 2016 in Amsterdam. It
summarizes progress in the biochemical marker ﬁeld by review-
ing the key published papers related to OA biomarkers and con-
tinues a theme established by the “Year in Review” papers
published on OA biomarkers over the last 5 years35,40e44. The
methodology involved searching the PubMed/MEDLINE biblio-
graphic database using the keywords ‘biomarker’ and ‘osteoar-
thritis’. In addition, the bibliographic databases were searched
using the keywords ‘biomarker’ and ‘proteomics’. The PubMed/
MEDLINE literature search was conducted using the Advanced
Search Builder function (http://www.ncbi.nlm.nih.gov/pubmed/
advanced) and speciﬁcally focused on the period between the
2015 and 2016 meetings.
Clinical validation of existing OA biomarkers
During the past year, OARSI has published a set of recommen-
dations for the use of soluble biomarkers in clinical trials. The
OARSI-endorsed publications summarize the key steps necessary
for the qualiﬁcation of a biomarker as a drug development tool and
the various contexts for which OA biomarkers may be used45,46. In
an effort to qualify more biomarkers as drug development tools, the
Foundation for the National Institutes of Health/Osteoarthritis
Initiative (FNIH/OAI) biomarkers consortiumef released the results
of their soluble (urinary, abbreviated with a preﬁx u and serum,
abbreviated with a preﬁx s) biomarker analysis45,46. Among the
important ﬁndings, the FNIH/OAI investigators found that time
integrated concentrations, over a 24-month period, of urinary C-
telopeptide of type II collagen (uCTX-II), serum hyaluronan (sHA)
and serum N-terminal telopeptide of type I collagen (sNTX-I) were
associated with subject cases that had both progressive pain and
radiographic progression of knee OA over a 4-year period (area
under the curve (AUC) 0.63). Baseline levels of uCTX-II and sNTX-I
predicted pain progression and radiographic progression (AUC
0.59). Plans are underway to qualify these biomarkers using sam-
ples and data from already completed DMOAD trials.
Several biomarkers have been tested in samples from patients
with varying severity of OA during the last year. However, there
were only a limited number of novel biomarkers; most were pre-
viously identiﬁed molecules such as matrix metalloproteinases
(MMPs), interleukins, adipokines and joint related serum bio-
markers MMP-degraded C-reactive protein (CRPM), MMP degraded
type III collagen (C3M), cartilage oligomeric matrix protein (COMP),
HA, N-terminal propeptide of collagen IIA (PIIANP), Col2-3/4 C-
terminal cleavage product of types I and II collagen, uCTX-II, matrix
metalloproteinase-3 (MMP-3) and urinary nitrated type II collagen
degradation fragment (uCol2-1 NO2)45,46. The ﬁrst analytical data
came from the OAI biomarker initiative where 18 biomarkers
believed to be associated with OAwere tested in 129 blood or urine
samples from OA patients45. The data showed that three
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(rho ¼ 0.19), PIIANP (rho ¼ 0.27) and C1,2C (rho ¼ 0.20). Likewise
gender differences were seen for uCTX-II, MMP-3, uCol2-1 NO2 and
sHA45. Cartilage damage and concentrations of sCOMP, sCTX-II,
sMMP-3, sPIIINP, and sHA were determined in 79 patients who
underwent knee arthroscopy or total knee replacement in a study
by Jiao and colleagues47. PIIANP, serum CTX-II, HA and COMP were
measured in this study, but only HA and COMP concentrations were
found to be signiﬁcantly higher in the knee OA patients with early
signs of cartilage damage47. These results suggest that sCOMP and
HA concentrations can be used to predict early cartilage lesions in
the knee. In the C4P study, 58 knee OA subjects and 33 healthy
controls were tested for the MMP derived collagen products C1M,
C2M, C3M together with CRP48. The knee OA patients had elevated
levels of C1M, C2M and CRP as compared to controls, whereas C3M
was signiﬁcantly lower48.
There have been a limited number of studies during the past year
that attempted to validate existing OA biomarkers in the context of a
clinical DMOAD trial. Karsdal et al.49 studied uCTX-I, uCTX-II and
serum osteocalcin in the context of two large phase III knee OA trials
of oral salmon calcitonin. The investigators found that in one trial
with a positive WOMAC pain response to calcitonin, there was a
reduction in all three markers over the 24-month trial. Unfortu-
nately, the pain and biomarker responses were not signiﬁcant at 24
months in the other calcitonin trial and there was a disparate
radiographic response between the two trials, making it difﬁcult to
validate the biomarkers as surrogates for either pain or radiographic
responses. The authors of the calcitonin clinical trial concluded that
a deﬁnitively successful DMOAD trial (i.e., a trial with a positive pain
and radiographic outcome) will be needed to validate predictive and
surrogate biomarkers for OA drug development.
There have been four reports from investigators studying large
OA cohorts that have addressed the predictive capability of estab-
lished OA biomarkers50e52. In one of these studies, sHA was asso-
ciated with JSWover a 5 year period in the Iwaki Health Promotion
Project50. In the Chingford cohort study, which has 20 years of data
on development of radiographic knee OA progression in a cohort of
middle-aged women with Kellgren and Lawrence (KL) scores of
zero at baseline, sCOMP levels in the highest quartile were signif-
icantly associated with the development of radiographic knee OA
and painful radiographic knee OA51. sCOMP was also shown to be
associatedwith increased 5-year risk of radiographic knee OAwhen
tested in 493 subjects with knee OA51. In the third report, 5-year
data from the Rotterdam study cohort was used to examine
biomarker associations with incidence of OA and KL progression53.
As noted by other investigators, uCTX-II and sCOMP were signiﬁ-
cantly associated with the incidence (deﬁned as KL < 2 at baseline
and KL  2 at follow-up) and progression (deﬁned as KL  1 in-
crease between baseline and follow-up) of OA53. In the ﬁnal report,
investigators analyzing 5-year data from the Cohort Hip and Cohort
Knee (CHECK) study, found that a number of biomarkers measured
at baseline were associated with the presence of baseline knee OA
(deﬁned as KL 1), incidence of knee OA (deﬁned as KL 0 at baseline
and KL  1 at follow-up) and progression of knee OA (deﬁned as KL
1 at baseline and KL  2 at follow-up). Interestingly, uCTX-II and
sCOMP were the most consistently associated biomarkers with the
presence, incidence and progression of knee OA52. While uCTX-II
and sCOMP were positively associated with the presence and pro-
gressionwith knee OA, both biomarkers were negatively associated
with the incidence of knee OA. The authors speculated that low
levels of cartilage and subchondral bone turnover in the earliest
phases of knee OA may explain this latter ﬁnding52.
The past year also included several publications that explored
the mechanisms and utility of established inﬂammatory bio-
markers in the pathogenesis of OA and as predictors of OAprogression. Data from the Rotterdam study indicated that akin to
uCTX-II and sCOMP, CRP was independently associated with the
incidence and progression of OA53. CRPM, uCTX-II and COMP were
independently and positively associated with OA progression53.
In ameta-analysis of knee, hip and hand OA studies from1992 to
2012, Jin and colleagues found that OA pain symptoms but not
radiographic ﬁndings were strongly correlated with high-
sensitivity C-reactive protein (hsCRP) levels54. As demonstrated
by Kraus and colleagues, one potential source of inﬂammation
driving CRP production may be inﬂammatory macrophages in the
joints of knee OA patients55. During this past year, this group of
investigators demonstrated that soluble markers of inﬂammatory
macrophages (CD14 and CD163) in the synovial ﬂuid (SF) and blood
were associated with the abundance of activated macrophages in
the knee joint as measured by EC20 SPECT imaging and these sol-
uble markers were associated with the severity of joint space nar-
rowing, osteophytes and knee pain56. Other well-knownmarkers of
inﬂammation were also validated in a study by Attur, Abramson
and colleagues57. Previously, this group had shown that peripheral
blood leukocyte transcript levels of the pro-inﬂammatory media-
tors interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a) and
cyclooxygenase-2 (COX-2) identiﬁed patients at risk for knee OA
disease progression58. In a 24 month prospective cohort of symp-
tomatic knee OA patients, the authors conﬁrmed that elevated
baseline levels of IL-1b, TNF-a and COX-2 peripheral blood tran-
scripts predicted a higher risk of JSW narrowing57. In another study
that analyzed samples from the same 24-month prospective cohort
of symptomatic knee OA patients, the authors found that plasma
levels of interleukin-1 receptor antagonist (IL-1Ra) were positively
associated with the severity and progression of knee OA59.
In addition to these ﬁndings, decreased serum and
SF uncarboxylated matrix Gla-protein (ucMGP) levels have been
detected in OA patients. The mean serum ucMGP levels of the knee
OA patients was signiﬁcantly lower than that of healthy controls
(P ¼ 0.045) and negatively correlated with radiographic severity
(r ¼ 0.48)60.
Other previously tested biomarkers were adipokines such as
leptin and adiponectin. Data from Gandhi et al. showed differences
between race61.
Mabey et al. showed that interleukin-4 (IL-4) and interleukin-6
(IL-6) levels were signiﬁcantly higher in OA patients compared to
controls and positively correlated with radiographic severity62.
In a study of 138 knee OA patients the serum levels of adipsin
(complement factor D), leptin, adiponectin, resistin and serpin E1,
and cartilage volume (MRI) were determined at baseline and 24
months. Higher levels of adipsin and leptin correlated with
increased cartilage volume in the global knee and medial femur.
Adiponectin showed an inverse correlation with cartilage volume
in the medial compartment and femur. Resistin and serpin E1 were
not associated with cartilage volume63.
Early testing of exploratory biomarkers
There have been some interesting studies published on different
proteomics approaches, including metabolomics, in the recent
period. Plasma proﬁles of 15 inﬂammation-related proteins were
signiﬁcantly different in farmers with musculoskeletal disease
(MSD) as compared to farmers without MSD64. Leucine-rich alpha-
2-glycoprotein, haptoglobin, complement factor B, serotransferrin,
one isoform of kininogen, one isoform of alpha-1-antitrypsin, and
two isoforms of hemopexin were higher in farmers with MSD than
in referents. On the other hand, the levels of alpha-2-HS-glyco-
protein, alpha-1B-glycoprotein, vitamin D-binding protein, apoli-
poprotein A1, antithrombin, one isoform of kininogen, and one
isoform of alpha-1-antitrypsin were lower in farmers with MSD
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may provide novel insight into biomarker developments. A
metabolomic proﬁle was done on urine samples of 22/22 OA
structural progressors/non-progressors (18-month follow-up) from
the Intensive Diet and Exercise for Arthritis (IDEA) trial. A proﬁle
including the following metabolites was found to be able to
discriminate between OA progressors and non-progressors: gly-
colate, hippurate, and trigonelline were among the important
metabolites for distinguishing progressors from non-progressors at
baseline whereas alanine, N,N-dimethylglycine, glycolate, hippu-
rate, histidine, and trigonelline distinguished between them at 18
months65. In another study, arginine was signiﬁcantly depleted in
refractory knee OA patients (n ¼ 64) vs controls (n ¼ 45), which is
most likely due to the over activity of arginine to ornithine
pathway, leading to imbalance between cartilage repair and
degradation66. These novel ﬁndings support a role for metabolic
factors in the severity (burden of disease) and progression of knee
OA and suggest that measurement of metabolites could be useful to
predict progression. Further investigation in a larger sample that
would include targeted investigation of speciﬁc metabolites is
warranted.
Biomarkers in interventional studies and clinical validation of
other existing markers
In a placebo controlled study in mild to moderate knee OA
(N ¼ 69) L-carnitine supplements was tested. Signiﬁcant changes to
IL-1b and MMP-1 were observed after treatment, which seemed to
be associated with decreases in visual analogue scale (VAS) pain67.
The biomarker-related studies published in the last 12 months
include some of the usual suspects such as COMP, HA, ADAMTS-4,
the aggrecan ARGS neo-epitope and the type II collagen markers
CTX-II, C2C and COLL2-1 NO2.
Adipokines (adipocytokines) presumably are an important
component of inﬂammatory OA68. There is evidence for racial
differences in OA prevalence and incidence69, and from general
population-based studies70. Some East Indian and Asian races
consistently demonstrate a unique adipokine/insulin serum
concentration proﬁle as compared to Caucasians and recent
ﬁndings published by Gandhi et al., suggest that race may be an
important factor to consider when studying serum biomarker
concentrations in OA61. This study also highlights the fact that
the ancestry of patients and research subjects should be taken
into consideration with respect to the design of OA biomarker
studies and also in connection with the analysis and presentation
of biomarker data.
Pascarelli et al.71, developed a randomized controlled trial to
study the effect of balneotherapy (mud-bath) therapy on serum
biomarkers in patients with knee OA. The authors observed a sta-
tistically signiﬁcant improvement in VAS pain and WOMAC sub-
scores but serum levels of COMP, myeloperoxidase (MPO) and
hsCRP did not show any signiﬁcant changes in either group. Inter-
estingly, a signiﬁcant increase in serum levels of CTX-II was
observed in the mud-bath group after the treatment and the au-
thors associate this increase with cartilage turnover induced by the
balneotherapy71. It is important to note that this is an unusual and
counter-intuitive observation that needs to be validated by other
studies.
Proteomics, novel OA biomarkers, new biomarker assays and
magnetic capture technologies
One of the more interesting technological advances during the
past year was the development of a magnetic nanoparticle-based
technology to collect biomarkers from a rodent stiﬂe, atechnology termed magnetic capture by the authors72. The authors
used anti-CTX-II antibodies conjugated to the surface of super-
paramagnetic iron oxide-containing polymeric particles to capture
and concentrate this biomarker directly in the affected joint in a rat
monoiodoacetate (MIA) model of knee OA. Importantly, measure-
ments were unaffected by SF viscosity. The development of such
technologies is important as it allows magnetic capture platforms
to be developed for a range of OA biomarkers. Ongoing work by the
same authors is aiming to facilitate optimization of the collection of
magnetic particle-biomarker conjugates from high-viscosity bio-
logical ﬂuids without the need to remove the ﬂuid from a patient73.
Proteomic techniques continue to remain a focus in biomarker
discovery and exploring the basic biology of articular cartilage and
other joint tissues. However, proteomic techniques developed for
other tissues need to be reﬁned and adapted for studies on articular
cartilage and chondrocytes. Hsueh and co-workers have advanced
the area of cartilage proteomics by reﬁning the extraction methods
for more in depth proteomic studies on the molecular composition
of cartilage74. They established and reﬁned a novel extraction
method for removing chondrocytes from cartilage sections with
minimal extracellular matrix protein loss. By adding surfactant to
guanidine-HCl extraction buffer they improved protein solubility
and used ultraﬁltration to remove interference from poly-
saccharides and salts. They also introduced in situ trypsin digestion
to increase the number of collagen peptides detectable from
cartilage bymass spectrometry (MS)74. The addition of surfactant to
guanidine-HCl extraction buffer allowed them to improve protein
solubility, which resulted in a four-fold increase in the extraction
and MS detection of collagen peptides by the in situ trypsin
digestion method. As expected, proteoglycans were far more
abundant within the guanidine-HCl extract. The methodology
developed by the authors will allow investigators to speciﬁcally
focus on the detection of extracellular matrix proteins from
different zones of articular cartilage and from diseased samples. For
those investigators interested in applying proteomics to chon-
drocytes and the membranome of these cells, proteomic methods
are being developed to enrich hydrophobic and hydrophilic protein
fractions. However, despite their best efforts, the total in situ
digestion method was not appropriate for identifying low abun-
dance proteins since the peptides from high abundant extracellular
proteins generally saturates the analytical performance system and
attenuated the ability to identify new proteins. This is a major
hurdle for identifying new and low abundance biomarkers with
clinical utility. Future studies on sub-compartments and carefully
generated fractions should allow investigators to focus on the
detection of lower abundance proteins.
Proteomics has also been applied to synovitis using an explant
model of the synovium. Kjelgaard-Petersen and colleagues primary
treated ﬁbroblast-like synoviocytes and synovial membrane ex-
plants (SMEs) with various pro-inﬂammatory cytokines and
growth factors and assessed the biological activity of the proteases
in this model using C1M, C3M, and active MMP-3 assays in the
conditioned medium from the cells and explants. Their work sug-
gests that C1M, C3M, and active MMP-3 may be used as biomarkers
of synovitis in ex vivomodels and provides a novel translational tool
for synovitis75.
At the present time there is insufﬁcient knowledge about the
chondrocyte membranome and its molecular composition. We
need to learn more about this proteome sub-compartment because
many potential drug targets reside in the plasma membrane of
living cells. New research from our own laboratory has developed a
Triton X-114 based separation technique using nano liquid chro-
matographyemass spectrometry/mass spectrometry (LCeMS/MS)
combined with shotgun proteomics to identify chondrocyte
membrane proteins76. Chondrocyte proteins were separated into
A. Mobasheri et al. / Osteoarthritis and Cartilage 25 (2017) 199e208204hydrophobic and hydrophilic fractions; and trypsin-digested frac-
tions were analyzed by nanoLC-MS/MS. A total of 315 proteins were
identiﬁed. The phase extraction method yielded a high proportion
of membrane proteins (56%) including CD276, S100 Calcium Bind-
ing Protein A6 (S100-A6 or calcyclin) and three voltage-dependent
anion-selective channel (VDAC) isoforms and several glucose
transporters. Our work has conﬁrmed the ﬁndings of several pre-
vious studies and adds new proteins to the proteomic proﬁle of
articular chondrocytes. Some of the identiﬁed proteins including
the CD276 antigen, S100-A6 or VDACs have not been previously
been reported to be components of articular chondrocytes. The
development and reﬁnement of proteomics-based techniques for
studying the chondrocyte membranome and other cellular sub-
compartments will enable a better understanding of the function
of regulatory proteins and enhance the search for new drug targets
for OA76.
Cathepsins are a family of lysosomal proteases that are thought
to contribute to OA pathophysiology due to their elevation and
activation in pro-inﬂammatory conditions. In order to monitor the
speciﬁc activity of cathepsins Ben-Aderet et al.77, developed a
cathepsin activity-based probe (ABP), GB123, for investigation of
enzyme activity in vitro and in vivo. In essence, these probes are
recognized by cathepsins and are conjugated on to the enzymes
after the reaction. Since the probes are tagged with a ﬂuorophore,
they emit ﬂuorescence that can be observed and quantiﬁed. The
ABPs allowed the investigators tomonitor cathepsin activity, which
was found to correlate well with OA severity and joint inﬂamma-
tion. The authors are developing biomarker assays for downstream
targets of cathepsins, thus allowing them to develop new assays
with translational potential for non-invasive detection of early OA
in preclinical models.
Identiﬁcation of novel cytokines and adipokines in the joint
Recent studies suggest that other cytokines may exert pro-
inﬂammatory effects on articular cartilage in synovial joints.
Conde et al., analyzed the expression of IL-36a in healthy and OA
cartilage and demonstrated that this cytokine acts as a pro-
inﬂammatory mediator in cartilage by increasing the expression
of markers of inﬂammation and cartilage catabolism including
MMP-13, nitric oxide synthase 2 (NOS-2) and COX-278. Like other
members of the interleukin family, IL-36a acts through the acti-
vation of nuclear factor kB (NFkB) and p38 MAPK pathway.
Therefore, IL-36a and its co-conspirators in the interleukin family
can co-operate with other pro-inﬂammatory cytokines and che-
mokines to enhance and perpetuate cartilage destruction78. EarlierDrug 
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adipokines produced by white adipose tissue (WAT) are implicated
in OA79. This work suggests that novel adipokines may exist in
different joint tissues and compartments and how these molecules
interact and are differentially expressed in healthy and OA joint
tissues is largely unknown. Advanced analytical (omics) techniques
are likely to identify novel biomarkers to shed more light on these
interactions between WAT-derived cytokines, joint inﬂammation
and cartilage degradation.
What's on the horizon in OA biomarker research?
Sleep and its physiological and pathophysiological attributes
are seldom considered to be “biomarkers” but new research in-
dicates that sleep is an important biological and disease marker.
There is increasing evidence to suggest that sleep is a patho-
physiological “marker” of disease progression. Sleep is a complex
biological process that involves cyclic changes of brain activity.
Sleep is a sensitive biomarker of brain function and depression.
Sleep dysregulation is closely linked to the underlying patho-
physiology of depressive disorders and sleep studies are essential
for antidepressant drug development. There is evidence that sleep
disturbance in OA is linked with pain and depression80. Depres-
sion plays a strong role in the sleep-pain linkage, particularly
where pain is severe and sleep is believed to have a unique and
predictive role in progression of disability. Sleep studies are not
done in conjunction with OA research but interdisciplinary
research involving sleep physiology may reveal novel in-
terventions to prevent OA-related functional decline among per-
sons whose sleep is disrupted by OA pain81 and this exciting
possibility can be explored in ongoing longitudinal cohorts or new
cohorts in future studies.
Conclusions
OA biomarker research is active and thriving. Applying the
biomarker toolbox in the drug discovery and development pathway
allows investigators to link a biomarker to a complementary
endpoint, thereby acting as a potential surrogate with predictive
power. This facilitates the drug discovery process and allows the
drug development industry to make rational economic decisions
about the continuity of preclinical studies and clinical trials. Bio-
markers can be used at critical decision points to make go/no-go
decisions. Biomarkers can be used in translational OA research,
bridging the gap between the bench and the bedside. Biomarkers
may also be used to identify responders and non-responders andNew 
Drug 
g 
Clinical  
Trials 
Qualification tion 
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tion of those in need of treatment and selection of patients most
likely to respond to treatment) (Fig. 3). In phase II clinical trials
biomarkers can be used for dose determination and safety/efﬁcacy
studies. They can also help pharmaceutical companies save costs by
enabling drug repositioning and determining the cost/beneﬁt ratio
for treatment. Biomarkers have the capacity to identify patients
who are in the greatest need of treatment, select those who may
respond optimally, with the greatest efﬁcacy and lowest safety
concerns to a speciﬁc treatment, enhancing drug development and
targeting strategies for a selected subpopulation of patients thus
allowing for more efﬁcient use of healthcare resources. Even in
routine clinical practice, biomarkers can be used as important
diagnostic and prognostic tools for monitoring disease develop-
ment and monitoring patient compliance with the recommended
therapy. They are also indispensable tools for pharmacovigilance,
personalized and precision health care and differentiating com-
pounds from competitors. However, from a clinical practice and
trial design perspective, none of the currently available biochemical
markers in our toolbox is sufﬁciently discriminating to aid diag-
nosis and prognosis of OA, or performs so consistently that it could
function as an outcome in clinical trials42. Speciﬁc biochemical
markers and categories of biochemical markers as well as their
speciﬁcity, origin and metabolism, need further investigation82.
Therefore, there is an urgent and unmet need to develop new
predictive biomarker tests that can provide an early warning of
joint alterations, which could prompt earlier, more targeted and
personalized treatments.
The aim of this “Year in Review” article is to discuss biomarker
related research and review articles published since the 2015 OARSI
congress. There has been solid and steady progress in OA biomarker
research since OARSI 2015. The OA biomarkers studies published in
the last year have included a set of recommendations from OARSI
for the use of soluble biomarkers in clinical trials outlining the key
steps necessary for the qualiﬁcation of a biomarker as a drug
development tool and the various contexts for which OA bio-
markers may be used. This is a major step forward in the clinical use
of OA biomarkers. In terms of new biomarkers there have been
important but incremental gains in our knowledge in the past year.
However, the majority of the published studies have represented
“evolutionary” rather than “revolutionary” increments in our
knowledge of OA.
We need more effort and faster progress in this area and this is
particularly important for OA patients. OARSI has submitted a
white paperg on December 1, 2016 asking the US Food and Drug
Administration (FDA) to consider OA as a serious disease. OARSI is
concerned about the growing population of OA patients, many of
whom may experience progressive disability and decreased
quality of life and the FDA has a unique and inﬂuential role in
fostering the development of these therapies, which might alter
the natural progression of OA. Novel OA biomarkers are needed
for subclinical or preclinical disease diagnosis and patient strati-
ﬁcation in clinical trials. OA biomarker research remains a chal-
lenging area, yet with many exciting opportunities for
collaboration between academic, drug development and clinical
scientists. Biomarkers can facilitate new research into the un-
derlying mechanisms in OA to validate existing biomarkers and
identify new candidates and subsets of OA patients that may have
differential responses to therapy. ‘Omics’ techniques and plat-
forms are continuously evolving and increasing in sensitivity,
which means that they can be used to identify novel OA subsets.g https://www.oarsi.org/sites/default/ﬁles/docs/2016/oarsi_white_paper_oa-
serious-disease.pdf.The reﬁnement of proteomic and immunoassay technologies is
also likely to contribute to improvements in diagnostic assays for
wet biochemical markers in serum, SF and urine. There are dif-
ferences in biomarkers between joints (knee, hip, hand, spine,
etc.) and more research is needed to explore whether there are
speciﬁc biomarkers for speciﬁc joints. The key challenges in OA
biomarker research include identiﬁcation of new and more sen-
sitive/speciﬁc biomarkers and improvement of existing biomarker
assays and the technologies and platforms used for their detection
and measurement. Another important issue is standardization
and calibration of biomarkers, enabling comparative studies. The
ultimate challenge for OA biomarker researchers is combining
biochemical and imaging markers into predictive algorithms and
new prognostic tests.
In conclusion, the capabilities of novel and exploratory bio-
markers for OA should be regarded as important capabilities for
furthering clinical research and patient stratiﬁcation. Nonetheless,
curiosity driven research that drives identiﬁcation of novel
exploratory OA biomarkers is worthy of further pursuit and should
remain a high priority. Further advances in OA biomarker qualiﬁ-
cation and progress towards the clinical utility of biochemical
markers will require highly stratiﬁed and well-phenotyped cohorts
that can be used for answering hypothesis driven research ques-
tions that can truly progress the current state-of-the art in OA
research.
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